Figure 2. hPMSCs upregulated the marker expression level of hGCs with POI. (A) FACS results indicated that hPMSCs increased the number of FSHR+AMH+ positive hGCs. (B) FACS results indicated that hPMSCs increased the number of CYP19A1+FOXL2+ positive hGCs. (C) Western blot results showed that hPMSCs increased the protein levels of FSHR, AMH, CYP19A1 and FOXL2 in POI hGCs to the normal level. All experiments were carried out three times; error bars indicate the SD; *** p < 0.001 (compared with the POI group). POI = premature ovarian insufficiency, hPMSC = human placental mesenchymal stem cell, hGCs = human ovarian granule cells.